Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes

被引:74
作者
Rosada, Rogerio S. [1 ]
de la Torre, Lucimara Gaziola [2 ]
Frantz, Fabiani G. [1 ,3 ]
Trombone, Ana P. F. [1 ]
Zarate-Blades, Carlos R. [1 ]
Fonseca, Denise M. [1 ]
Souza, Patricia R. M. [1 ]
Brandao, Izaira T. [1 ]
Masson, Ana P. [1 ]
Soares, Edson G. [4 ]
Ramos, Simone G. [4 ]
Faccioli, Lucia H. [3 ]
Silva, Celio L. [1 ]
Santana, Maria H. A. [2 ]
Coelho-Castelo, Arlete A. M. [1 ]
机构
[1] Univ Sao Paulo, Fac Med Ribeirao Preto, Nucleo Pesquisas Tuberculose, Sao Paulo, Brazil
[2] Univ Estadual Campinas, Fac Engn Quim, Dept Proc Biotecnol, Sao Paulo, Brazil
[3] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Dept Anal Clin Toxicol & Bromatol, Sao Paulo, Brazil
[4] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Patol, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
D O I
10.1186/1471-2172-9-38
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The greatest challenges in vaccine development include optimization of DNA vaccines for use in humans, creation of effective single-dose vaccines, development of delivery systems that do not involve live viruses, and the identification of effective new adjuvants. Herein, we describe a novel, simple technique for efficiently vaccinating mice against tuberculosis (TB). Our technique consists of a single-dose, genetic vaccine formulation of DNA-hsp65 complexed with cationic liposomes and administered intranasally. Results: We developed a novel and non-toxic formulation of cationic liposomes, in which the DNA-hsp65 vaccine was entrapped (ENTR-hsp65) or complexed (COMP-hsp65), and used to immunize mice by intramuscular or intranasal routes. Although both liposome formulations induced a typical Th1 pattern of immune response, the intramuscular route of delivery did not reduce the number of bacilli. However, a single intranasal immunization with COMP-hsp65, carrying as few as 25 mu g of plasmid DNA, leads to a remarkable reduction of the amount of bacilli in lungs. These effects were accompanied by increasing levels of IFN-gamma and lung parenchyma preservation, results similar to those found in mice vaccinated intramuscularly four times with naked DNA-hsp65 (total of 400 mu g). Conclusion: Our objective was to overcome the significant obstacles currently facing DNA vaccine development. Our results in the mouse TB model showed that a single intranasal dose of COMP-hsp65 elicited a cellular immune response that was as strong as that induced by four intramuscular doses of naked-DNA. This formulation allowed a 16-fold reduction in the amount of DNA administered. Moreover, we demonstrated that this vaccine is safe, biocompatible, stable, and easily manufactured at a low cost. We believe that this strategy can be applied to human vaccines to TB in a single dose or in prime-boost protocols, leading to a tremendous impact on the control of this infectious disease.
引用
收藏
页数:13
相关论文
共 54 条
[31]  
Klavinskis LS, 1999, J IMMUNOL, V162, P254
[32]   Therapeutic potential of Toll-like receptor 9 activation [J].
Krieg, Arthur M. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (06) :471-484
[33]   Single dose of a vaccine based on DNA encoding mycobacterial hsp65 protein plus TDM-loaded PLGA microspheres protects mice against a virulent strain of Mycobacterium tuberculosis [J].
Lima, KM ;
Santos, SA ;
Lima, VMF ;
Coelho-Castelo, AAM ;
Rodrigues, JM ;
Silva, CL .
GENE THERAPY, 2003, 10 (08) :678-685
[34]   Therapy of tuberculosis in mice by DNA vaccination [J].
Lowrie, DB ;
Tascon, RE ;
Bonato, VLD ;
Lima, VMF ;
Faccioli, LH ;
Stavropoulos, E ;
Colston, MJ ;
Hewinson, RG ;
Moelling, K ;
Silva, CL .
NATURE, 1999, 400 (6741) :269-271
[35]   Development of an antigen-presenting cell-targeted DNA vaccine against melanoma by mannosylated liposomes [J].
Lu, Yan ;
Kawakami, Shigeru ;
Yamashita, Fumiyoshi ;
Hashida, Mitsuru .
BIOMATERIALS, 2007, 28 (21) :3255-3262
[36]   First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response [J].
MacGregor, RR ;
Boyer, JD ;
Ugen, KE ;
Lacy, KE ;
Gluckman, SJ ;
Bagarazzi, ML ;
Chattergoon, MA ;
Baine, Y ;
Higgins, TJ ;
Ciccarelli, RB ;
Coney, LR ;
Ginsberg, RS ;
Weiner, DB .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (01) :92-100
[37]   Safety and immunogenicity of DNA/modified vaccinia virus Ankara malaria vaccination in African adults [J].
Moorthy, VS ;
Pinder, M ;
Reece, WHH ;
Watkins, K ;
Atabani, S ;
Hannan, C ;
Bojang, K ;
McAdam, KPWJ ;
Schneider, J ;
Gilbert, S ;
Hill, AVS .
JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (08) :1239-1244
[38]   Increased antimycobacterial immunity in interleukin-10-deficient mice [J].
Murray, PJ ;
Young, RA .
INFECTION AND IMMUNITY, 1999, 67 (06) :3087-3095
[39]   Mice incapable of making IL-4 or IL-10 display normal resistance to infection with Mycobacterium tuberculosis [J].
North, RJ .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1998, 113 (01) :55-58
[40]  
O'Hagan Derek T, 2003, Expert Rev Vaccines, V2, P269, DOI 10.1586/14760584.2.2.269